Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex–induced lung disease
Nelli Shushakova, … , Reinhold E. Schmidt, J. Engelbert Gessner
Nelli Shushakova, … , Reinhold E. Schmidt, J. Engelbert Gessner
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1823-1830. https://doi.org/10.1172/JCI16577.
View: Text | PDF
Article Autoimmunity

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex–induced lung disease

  • Text
  • PDF
Abstract

Research Article

Authors

Nelli Shushakova, Julia Skokowa, Jurriaan Schulman, Ulrich Baumann, Jörg Zwirner, Reinhold E. Schmidt, J. Engelbert Gessner

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Attenuation of IC-induced lung injury by C5aR and FcγRIII deficiency. C5...
Attenuation of IC-induced lung injury by C5aR and FcγRIII deficiency. C57BL/6 WT (filled circles), FcγRIII–/– (filled squares), and C5aR–/– (filled triangles) mice received 150 μg anti-OVA Ab intratracheally and 20 mg/kg OVA Ag intravenously, and the inflammatory response in the lung was allowed to proceed for 2 to 24 hours (IC). Mice not receiving OVA Ag served as Ab controls (open circles). At the indicated times, mice were killed, and PMN accumulation in lung tissue (a), PMN influx in the alveolar space (b), and hemorrhage (c), were evaluated. The results are expressed as means ± SEM (n = 7–18 mice for each group). Differences for hemorrhage and alveolar and interstitial PMN infiltration were significant (P < 0.05) for the IC treatment groups of WT mice as compared with FcγRIII–/– and C5aR–/– mice at 4, 8, and 24 hours. FcγRIII–/– and C5aR–/– mice only differed significantly for alveolar PMN accumulation (see text). Ab control values do not differ between WT, FcγRIII–/–, and C5aR–/– mice (data not shown).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts